ACL & Ligament Injuries
Peptides discussed for ACL tears, ACL surgery recovery, MCL injuries, and ankle sprains — BPC-157, TB-500, GHK-Cu — with the rat ligament evidence, why a torn ACL is a different problem from a sprain, and what no peptide has been shown to do.
Ligaments connect bone to bone and stop joints from moving in directions they shouldn't. Three ligament injuries account for most of the 'peptides for ligament' searches. The anterior cruciate ligament (ACL) sits in the center of the knee and controls forward sliding and rotation of the shin bone; it usually tears during a pivot, cut, or awkward landing, often with an audible pop, swelling within hours, and a knee that later 'gives way'. The medial collateral ligament (MCL) runs along the inner knee and is typically injured by a blow or force that pushes the knee inward. Lateral ankle sprains — rolling the ankle — stretch or tear the small ligaments on the outside of the ankle and are among the most common injuries in sport. All are graded from I (stretched) to III (completely torn).
These ligaments have very different capacities to heal. The MCL sits outside the joint, has a good blood supply, and heals well: isolated MCL injuries are usually treated without surgery, with bracing and rehab. Grade I–II ankle sprains also heal with functional treatment — a brace or tape plus an exercise program — and the Dutch evidence-based guideline reserves surgery for the minority that do not respond. The ACL is the outlier. It lives inside the joint, bathed in synovial fluid, with a limited blood supply, and when it ruptures completely the torn ends usually do not reconnect into a functional ligament on their own. That conventional teaching has recently been nuanced — in the KANON trial, MRI showed ACL continuity at two years in about a third of people assigned to rehab first, and an Australian cross-bracing protocol reported continuity in most patients at three months — but those findings come from specific rehab and bracing approaches, not drugs, and are still being tested.
For a torn ACL, the main choice is between reconstruction (replacing the ligament with a tendon graft) and structured rehab with reconstruction later if the knee stays unstable. In the KANON randomized trial of young, active adults, the two strategies produced similar outcomes at two years, and the rehab-first strategy avoided surgery in many participants. After reconstruction, the graft has to remodel over many months and integrate into bone tunnels, and most return-to-sport programs run around nine months or longer. That long, slow biology is why BPC-157 and TB-500 are so widely discussed for ACL recovery. This page covers what the evidence actually shows, and does not show. It is informational, not medical advice.
Peptides discussed for ACL & Ligament Injuries
GHK-Cu
Copper Peptide
The most-studied copper peptide in skincare — a naturally occurring tripeptide (GHK, Gly-His-Lys) whose active tissue form is the copper complex GHK-Cu, with extensive evidence for skin remodeling, collagen synthesis, wound healing, and anti-aging.
BPC-157
Gastric Peptide
A synthetic peptide derived from a protective protein found in gastric juice, widely discussed for tissue repair and recovery.
TB-500
Tissue Repair Peptide
A synthetic version of the active region of thymosin beta-4, widely used for tissue repair, wound healing, and recovery from injuries.
How peptides target acl & ligament injuries
BPC-157's ligament reputation rests mainly on one study. Cerovecki and colleagues (Journal of Orthopaedic Research, 2010) surgically cut the medial collateral ligament in rats and treated them with BPC-157 given by intraperitoneal injection, in drinking water, or as a thin topical cream over the injury. Across 90 days, treated rats showed better function, stronger biomechanics, and better tissue appearance under the microscope than controls. The same research group reports faster healing of cut Achilles tendons and of tendon detached from bone — the second being the closest animal analogue to what an ACL graft has to do inside its bone tunnels. The proposed mechanisms are the familiar BPC-157 set: growth factor upregulation (VEGF, EGF, FGF), new blood vessel formation, nitric oxide signaling, and better-organized collagen.
TB-500 is the synthetic fragment marketed as thymosin beta-4's active region, and it is usually stacked with BPC-157. Its ligament evidence is a 2013 rat study in which a single dose of full-length thymosin beta-4 — 1 microgram in fibrin sealant — was placed directly into the gap of a cut MCL; at four weeks the healing tissue had more organized collagen fibers and better mechanical properties. That was the full-length protein applied locally, not systemic injections of the TB-500 fragment people actually buy.
GHK-Cu is occasionally added for its effects on collagen synthesis and matrix remodeling, but its evidence is from skin and wound models. There are no ligament-specific GHK-Cu data.
The most important detail is which ligament was studied. Both key animal studies used the MCL — the ligament that already heals well in people. We could not find a published study of BPC-157 or TB-500 in an ACL injury model or an ACL graft model. The jump from 'helps a rat MCL heal' to 'helps a human ACL or ACL graft' is two steps of extrapolation, not one.
What the evidence shows
There is no randomized trial of any peptide for ACL tears, ACL reconstruction recovery, MCL injuries, or ankle sprains, and there are no human data at all on ACL graft healing with peptides. The only published human orthopaedic data for BPC-157 is a 2021 retrospective chart review from a single Florida practice: 16 people with assorted causes of knee pain received intra-articular BPC-157, some combined with thymosin beta-4, and were later surveyed by phone. Most reported improvement, but there was no control group, no validated outcome measure, no imaging, and the underlying causes of knee pain were mixed. It cannot tell anyone whether a peptide helps a ligament heal.
The animal-to-human gap is wide. The rat studies used clean, surgically created cuts in young animals whose ligaments heal readily; a human ACL rupture is a frayed tear inside a joint where synovial fluid works against clot formation, and a reconstruction graft is a different tissue again. Nearly all of the BPC-157 musculoskeletal work comes from one research group in Zagreb, and independent replication is limited.
Conventional care has a much stronger evidence base. The AAOS clinical practice guideline on ACL injuries sets out the evidence for reconstruction, graft choice, and rehabilitation. The KANON trial showed that rehab with optional delayed reconstruction matched early reconstruction at two years in young, active adults. For ankle sprains, the 2018 Dutch guideline recommends functional treatment with tape or a brace plus supervised exercise over passive treatments, cautions that NSAIDs may suppress natural healing, and reserves surgery for people who fail thorough rehab. Peptides do not change any of these decisions.
What to expect
Protocols commonly discussed — not prescriptions — are BPC-157 at 200–500 mcg by subcutaneous injection once or twice daily for about four weeks, sometimes extended to six to eight, and TB-500 at 2–2.5 mg twice weekly for a four-to-six-week loading phase, then about 2 mg every one to two weeks. These numbers come from clinic and community practice, not human dose-ranging trials, and should only be used with a clinician who knows your diagnosis.
For MCL sprains and grade I–II ankle sprains, the realistic baseline is that these injuries heal anyway, typically over weeks to a few months with good rehab. People who feel they recovered faster on a peptide cannot know what their recovery would have been without it. If an ankle keeps giving way months after a sprain, that points to chronic instability that needs balance and strength work, and sometimes surgical assessment — not a longer peptide course.
For a completely torn ACL, do not expect a peptide to restore stability. Whether your knee gives way during pivoting is what drives the reconstruct-or-rehab decision, and nothing in the peptide evidence changes that. Early specialist assessment matters, because some emerging non-surgical approaches, such as cross-bracing, are only an option within weeks of the injury. After reconstruction, there is no evidence that peptides speed graft maturation or shorten the timeline for safe return to sport. Infection inside a reconstructed knee is one of the most serious complications of ACL surgery and can cost the graft, so injecting unregulated research-chemical product into or near the knee is a real risk with no proven benefit. Discuss anything you plan to take with your surgeon.
Important caveats
Get prompt in-person evaluation, not a peptide protocol, if you felt a pop and the knee swelled within hours (bleeding into the joint usually means an ACL tear or fracture); if the knee locks, catches, or won't straighten fully (a displaced meniscus tear can need urgent surgery); if you cannot put weight on the leg; or if, after an ankle injury, you cannot take four steps or have tenderness over the ankle bones or the outer edge of the foot (possible fracture). A knee that has dislocated, or a cold, pale, or numb foot after a knee injury, is an emergency because the artery behind the knee can be damaged. Calf pain and swelling after an injury or surgery can be a blood clot. Fever, redness, or a hot, swollen joint after surgery needs same-day review.
ACL tears are common in teenagers. BPC-157 and TB-500 have no pediatric safety data, and people under 18 should not use them. The same applies to anyone pregnant, breastfeeding, or with active or recent cancer, given the angiogenic, growth-factor-driven mechanisms.
None of these peptides is FDA-approved for any ligament injury. BPC-157 and TB-500 were removed from the FDA's 503A 'Category 2' list in April 2026, and the Pharmacy Compounding Advisory Committee voted 8–6 in July 2026 to recommend both for the 503A bulks list; that vote is non-binding and the required rulemaking has not happened, so compounding remains unauthorized. GHK-Cu is legal as a topical cosmetic ingredient; injectable GHK-Cu is not FDA-approved. BPC-157 is named on the 2026 WADA Prohibited List under S0 (non-approved substances) and TB-500 under S2.3 (thymosin-β4 derivatives) — both banned at all times. Tested athletes should assume systemic GHK-Cu is prohibited under S0.
Frequently asked questions
Can peptides heal a torn ACL?
There is no evidence that any peptide heals a completely torn ACL. The ligament sits inside the joint with a poor blood supply, and the torn ends usually do not reconnect into a functional ligament on their own. Emerging research shows some ACL ruptures can regain continuity with specific bracing and rehab protocols, but that has nothing to do with peptides. The animal ligament data for BPC-157 and TB-500 come from the MCL, a ligament that already heals well. No study has tested either peptide in an ACL injury.
Does BPC-157 help ACL recovery?
No human study has tested it. The interest comes from rat studies: BPC-157 improved healing of a cut MCL and of tendon detached from bone, and the second is loosely analogous to how an ACL graft heals into bone tunnels. That is a plausible mechanism, not evidence. A 2025 systematic review found 35 of 36 BPC-157 musculoskeletal studies were preclinical and that no clinical safety data exist. BPC-157 is also banned by WADA, which matters because many people recovering from ACL surgery are competitive athletes.
Should I use peptides after ACL surgery?
Raise it with your surgeon before using anything. There are no human data on peptides and ACL graft healing, and no evidence they shorten the roughly nine-month-plus timeline for safe return to pivoting sport. Graft remodeling is slow for biological reasons that a few weeks of injections are unlikely to override. Infection inside a reconstructed knee is a serious complication, so non-sterile research-chemical products are a real concern. What does change ACL outcomes is consistent, criteria-based rehab.
What are the best peptides for ligament injuries?
BPC-157 has the most ligament-specific animal data (a 2010 rat MCL study), and TB-500 is usually stacked with it on the strength of a 2013 rat MCL study using full-length thymosin beta-4. GHK-Cu is sometimes added but has no ligament-specific evidence. None has been tested in human ligament injuries, none is FDA-approved, and BPC-157 and TB-500 are prohibited by WADA. Ligaments that heal well on their own, like the MCL and most ankle ligaments, are where any benefit would be hardest to detect.
Can peptides help an ankle sprain heal faster?
There are no studies of peptides in ankle sprains. Grade I–II sprains heal with functional treatment — a brace or tape, early weight-bearing as tolerated, and balance and strength exercises — and the evidence-based guideline favors supervised exercise over passive treatments. The bigger long-term issue after an ankle sprain is recurrence, and balance training and bracing, not peptides, are what reduce it. A sprain that leaves you unable to walk, or with tenderness over the ankle bones, needs an X-ray first.
Do peptides help with a partial ACL tear or an MCL tear?
Partial ACL tears and MCL tears are the injuries where a healing adjunct is at least biologically plausible, because some ligament tissue remains to heal. But both are often managed successfully with bracing and rehab, there are no human peptide trials for either, and the rat MCL results have not been replicated in people. If you try a peptide, do it under a clinician's supervision and alongside the rehab program, and judge progress by function and stability rather than pain alone.
References
- Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the ratPreclinical
Cerovecki and colleagues, Journal of Orthopaedic Research 2010. Surgically transected rat MCL treated with BPC-157 intraperitoneally, orally in drinking water, or as a topical cream; consistent functional, biomechanical, macroscopic, and histological improvements over 90 days. The core study behind 'BPC-157 for ligaments' — but in the MCL, which already heals well in people, not the ACL.
- Thymosin β4 enhances the healing of medial collateral ligament injury in ratPreclinical
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee PainCase Series
- A randomized trial of treatment for acute anterior cruciate ligament tearsRandomized Controlled Trial
Frobell and colleagues, New England Journal of Medicine 2010 (the KANON trial). In 121 young, active adults with acute ACL tears, rehab plus early reconstruction was not superior at two years to rehab with optional delayed reconstruction, and the rehab-first strategy substantially reduced the number of reconstructions.
- Evidence of ACL healing on MRI following ACL rupture treated with rehabilitation alone may be associated with better patient-reported outcomes: a secondary analysis from the KANON trialCohort Study
- Healing of acute anterior cruciate ligament rupture on MRI and outcomes following non-surgical management with the Cross Bracing ProtocolCase Series
- American Academy of Orthopaedic Surgeons Clinical Practice Guideline Summary: Management of Anterior Cruciate Ligament InjuriesClinical Guideline
- Diagnosis, treatment and prevention of ankle sprains: update of an evidence-based clinical guidelineClinical Guideline
Part of these goals
Related conditions
Peptide families relevant to ACL & Ligament Injuries
Thymic Peptides
The peptide family derived from thymic tissue and its synthetic analogs — Thymosin α-1 (Zadaxin / thymalfasin, immune modulation), Thymosin β-4 (TB-500, tissue repair through actin sequestration), Thymalin (Russian-tradition thymic-extract preparation), Thymulin (zinc-dependent thymic hormone), and Thymagen (Khavinson-program synthetic thymic peptide). Two functional branches: α-family for immune function, β-family for actin-mediated tissue repair.
Copper Peptides
A family of small copper-binding tripeptides — GHK-Cu, AHK-Cu, and palmitoyl variants — that form stable copper(II) complexes with documented effects on collagen synthesis, wound healing, and skin remodeling. Founded by Loren Pickart's 1973 isolation of GHK-Cu and now a fixture of cosmetic dermatology and the wound-care literature.
Stacks that overlap
- GLOW Peptide Stack (BPC-157 + TB-500 + GHK-Cu)
GLOW is a popular pre-mixed compounded peptide blend combining BPC-157 tissue repair, TB-500 cell migration, and GHK-Cu collagen remodeling in a single 70 mg vial. Also covers the two-peptide BPC-157 + GHK-Cu pairing for practitioners sourcing vials separately.
- KLOW Peptide Stack (BPC-157 + TB-500 + GHK-Cu + KPV)
KLOW is a pre-mixed four-peptide compounded blend combining BPC-157 and TB-500 systemic repair, GHK-Cu collagen remodeling, and KPV anti-inflammatory coverage in a single 80 mg vial. It extends the popular GLOW formulation with an explicit anti-inflammatory layer.
- Wolverine Peptide Stack (BPC-157 + TB-500)
The Wolverine Stack is the most popular peptide recovery combination — BPC-157 for localized tissue repair paired with TB-500 for systemic healing, cell migration, and anti-inflammatory support.
Updated 2026-10-05